IL6 and cancer: Combination of polyI:C and anti-IL6 antibody enhanced polyI:C-suppressions of survival, oncogenicity, and metastasis of A549 and potentially other cancer cells, as long as they express sufficient but non-saturating levels of functional TLR3 protein.